X

Trial Profile

A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BLU 701 (Primary) ; Carboplatin; Osimertinib; Pemetrexed
Indications Non-small cell lung cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms Harmony
Sponsors Blueprint Medicines

Most Recent Events

15 Jun 2023 Status changed from active, no longer recruiting to discontinued.
12 Jan 2023 Status changed from recruiting to active, no longer recruiting.
09 Aug 2022 Trial design presented at the 2022 World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com